Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) FCF Margin (2016 - 2025)

Historic FCF Margin for Agios Pharmaceuticals (AGIO) over the last 13 years, with Q3 2025 value amounting to 696.48%.

  • Agios Pharmaceuticals' FCF Margin rose 2477100.0% to 696.48% in Q3 2025 from the same period last year, while for Sep 2025 it was 924.5%, marking a year-over-year increase of 797700.0%. This contributed to the annual value of 1072.73% for FY2024, which is 347500.0% up from last year.
  • As of Q3 2025, Agios Pharmaceuticals' FCF Margin stood at 696.48%, which was up 2477100.0% from 626.25% recorded in Q2 2025.
  • Over the past 5 years, Agios Pharmaceuticals' FCF Margin peaked at 626.25% during Q2 2025, and registered a low of 12084.01% during Q1 2022.
  • For the 4-year period, Agios Pharmaceuticals' FCF Margin averaged around 1896.4%, with its median value being 1221.25% (2024).
  • In the last 5 years, Agios Pharmaceuticals' FCF Margin soared by 103799300bps in 2023 and then plummeted by -2262600bps in 2024.
  • Over the past 4 years, Agios Pharmaceuticals' FCF Margin (Quarter) stood at 1537.73% in 2022, then surged by 33bps to 1023.82% in 2023, then decreased by -22bps to 1250.08% in 2024, then surged by 44bps to 696.48% in 2025.
  • Its last three reported values are 696.48% in Q3 2025, 626.25% for Q2 2025, and 1286.44% during Q1 2025.